• Akari held its annual general meeting on June 30, 2026.
• Shareholders adopted the annual report and accounts for the year ended Dec. 31, 2025.
• Advisory votes backed the directors’ remuneration report, the directors’ remuneration policy, and the compensation of named executive officers.
• Director reappointments for Hoyoung Huh, Robert Bazemore, James Neal, Sandip I. Patel, Samir R. Patel, Abizer Gaslightwala were approved.
• BDO USA was ratified as independent registered public accounting firm for 2026; HaysMac was reappointed as statutory auditor; the audit committee was authorized to set auditor pay.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031972), on July 02, 2026, and is solely responsible for the information contained therein.